IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLI

William Sandborn  ¹     Marla C. Dubinsky  ²     Joana Torres  ³     Severine Vermeire  ⁴     Paulo Kotze  ⁵     Chinyu Su  ⁶     Nervin Lawendy  ⁶     Jerome Paulissen  ⁷     Rajiv Mundayat  ⁷     Sean Gardiner  ⁷     nicole kulisek  ⁷     Irene Modesto  ⁷     Geert R. D'Haens  ^8    
1 University of California, La Jolla, United States
² Icahn School of Medicine at Mount Sinai, New York, United States
³ Hospital Beatriz Ângelo, Loures and Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
⁴ University Hospitals Leuven, Leuven, Belgium
⁵ Catholic University of Paraná, IBD Outpatient Clinics, Colorectal Surgery Unit, Curitiba, Brazil
⁶ Pfizer Inc, Collegeville, United States
⁷ Pfizer Inc, New York, NY, United States
⁸ Amsterdam University Medical Centres, Amsterdam, Netherlands

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)